Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer

BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yuki, Kobayashi, Tetsu, Nishii, Yoichi, Suzuki, Yuta, Saiki, Haruko, Ito, Kentaro, Watanabe, Fumiaki, Nishihama, Kota, Yasuma, Taro, D'Alessandro‐Gabazza, Corina N., Katsuta, Koji, Fujimoto, Hajime, Gabazza, Esteban C, Taguchi, Osamu, Hataji, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/
https://www.ncbi.nlm.nih.gov/pubmed/30209885
http://dx.doi.org/10.1111/1759-7714.12861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/
https://www.ncbi.nlm.nih.gov/pubmed/30209885
http://dx.doi.org/10.1111/1759-7714.12861

Ejemplares similares